Beta Bionics Inc [BBNX] stock is trading at $24.28, up 2.23%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BBNX shares have gain 15.73% over the last week, with a monthly amount glided 22.29%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Goldman upgraded its rating to Buy on October 01, 2025, and kept the price target unchanged to $26. On June 16, 2025, Truist initiated with a Buy rating and assigned a price target of $26 on the stock. Lake Street started tracking the stock assigning a Buy rating and suggested a price target of $30 on June 12, 2025. Wolfe Research initiated its recommendation with a Outperform and recommended $20 as its price target on May 30, 2025. Goldman started tracking with a Neutral rating for this stock on May 30, 2025, and assigned it a price target of $16. In a note dated February 24, 2025, Stifel initiated an Buy rating and provided a target price of $25 on this stock.
Beta Bionics Inc [BBNX] stock has fluctuated between $8.89 and $26.66 over the past year. Currently, Wall Street analysts expect the stock to reach $21.5 within the next 12 months. Beta Bionics Inc [NASDAQ: BBNX] shares were valued at $24.28 at the most recent close of the market. An investor can expect a potential drop of -11.45% based on the average BBNX price forecast.
Analyzing the BBNX fundamentals
Beta Bionics Inc [NASDAQ:BBNX] reported sales of 78.02M for the trailing twelve months, which represents a growth of 54.45%. Gross Profit Margin for this corporation currently stands at 0.54% with Operating Profit Margin at -0.8%, Pretax Profit Margin comes in at -0.94%, and Net Profit Margin reading is -0.94%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is -0.41 and Total Capital is -0.2. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.53 points at the first support level, and at 22.79 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.95, and for the 2nd resistance point, it is at 25.62.
Ratios To Look Out For
For context, Beta Bionics Inc’s Current Ratio is 14.68. Further, the Quick Ratio stands at 13.79, while the Cash Ratio is 1.8. Considering the valuation of this stock, the price to sales ratio is 13.53, the price to book ratio is 3.50.
Transactions by insiders
Recent insider trading involved Feider Stephen, Chief Financial Officer, that happened on Oct 03 ’25 when 4982.0 shares were sold. Chief Financial Officer, Feider Stephen completed a deal on Oct 01 ’25 to sell 15018.0 shares. Meanwhile, Officer Stephen Feider bought 4982.0 shares on Oct 03 ’25.
